Page last updated: 2024-09-04

docetaxel anhydrous and lycopene

docetaxel anhydrous has been researched along with lycopene in 2 studies

Compound Research Comparison

Studies
(docetaxel anhydrous)
Trials
(docetaxel anhydrous)
Recent Studies (post-2010)
(docetaxel anhydrous)
Studies
(lycopene)
Trials
(lycopene)
Recent Studies (post-2010) (lycopene)
12,1103,2166,9203,0782741,634

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Fruehauf, J; Lilly, M; Parmakhtiar, B; Simoneau, AR; Tang, Y; Xie, J; Zi, X1
Fruehauf, JP; Lilly, M; Uchio, E; Zhuang, E; Zi, X1

Trials

1 trial(s) available for docetaxel anhydrous and lycopene

ArticleYear
A phase II study of docetaxel plus lycopene in metastatic castrate resistant prostate cancer.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021, Volume: 143

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; California; Disease Progression; Docetaxel; Humans; Kallikreins; Lycopene; Male; Middle Aged; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Time Factors

2021

Other Studies

1 other study(ies) available for docetaxel anhydrous and lycopene

ArticleYear
Lycopene enhances docetaxel's effect in castration-resistant prostate cancer associated with insulin-like growth factor I receptor levels.
    Neoplasia (New York, N.Y.), 2011, Volume: 13, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Carotenoids; Cell Line, Tumor; Docetaxel; Humans; Lycopene; Male; Mice; Mice, Nude; Prostatic Neoplasms; Receptor, IGF Type 1; Taxoids; Xenograft Model Antitumor Assays

2011
chemdatabank.com